Mosapride combined with rebamipide demonstrates superior efficacy for treatment of chronic atrophic gastritis

Abstract

Objective: To evaluate the therapeutic efficacy of combining mosapride with rebamipide for treatment of chronic atrophic gastritis (CAG).

Methods: A total of 116 patients with confirmed CAG were enrolled. The control group (n=52) received mosapride alone, while the observation group (n=64) was treated with both mosapride and rebamipide. Therapeutic outcomes, adverse events, pathological scores, symptom relief time, and serological markers were compared between the groups. Univariate and multivariate analyses were also conducted to identify factors influencing treatment efficacy.

Results: The observation group exhibited a significantly higher overall effective rate than the control group (P<0.05), with no significant difference in adverse events (P>0.05). Pathological scores were significantly lower in the observation group both compared to baseline and to the control group (P<0.05). Additionally, the observation group had greater improvements in all serological markers and a shorter duration to symptom relief (all P<0.05). Multivariate analysis identified smoking history (P=0.017, OR=4.318), alcohol consumption history (P=0.002, OR=6.327), and epidermal growth factor levels (P=0.044, OR=3.394) as independent risk factors for treatment response.

Conclusion: The combination of mosapride and rebamipide offers superior efficacy in managing CAG without increasing adverse effects. It significantly improves pathological conditions, expedites symptom resolution, and enhances gastric mucosal biomarker profiles, supporting its broader clinical application.

Keywords: Mosapride; chronic atrophic gastritis; efficacy; influencing factors; rebamipide.

Figure 1

Comparative analysis of pathological scores. A. Gastric mucosal inflammation scores of the two groups before and after treatment. B. Gastric mucosal inflammation pathological scores before and after medication in the two groups. Note: ^aP<0.05, ^bP<0.01, when compared to the pre-treatment values; ^cP<0.05, when compared to the control group.

Figure 2

Comparative analysis of serological markers. A. G-17 levels of the two groups before and after treatment. B. PGI levels of the two groups before and after treatment. C. EGF levels of the two groups before and after treatment. Note: ^aP<0.05, ^bP<0.01, when compared to the pre-treatment values; ^cP<0.05, when compared to the control group. G-17, gastrin 17; PGI, pepsinogen I; EGF, epidermal growth factor.